CD8A and breast cancer: Our study confirms that pharmaceutical inhibition of Th2-mediated immunity by IPD could elicit an antitumor immune response against breast cancer by enhancing the antitumor activity of cytotoxic CD8+ T and modulating the global immune landscape of TME.